Jerin Samanta, Harvey Amanda J, Lewis Annabelle
Centre for Genome Engineering and Maintenance, Division of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK.
Centre for Genome Engineering and Maintenance, Institute for Health Medicine and Environments, Brunel University London, Uxbridge UB8 3PH, UK.
Cancers (Basel). 2023 Jul 21;15(14):3703. doi: 10.3390/cancers15143703.
PTK6, a non-receptor tyrosine kinase, modulates the pathogenesis of breast and prostate cancers and is recognized as a biomarker of breast cancer prognosis. There are over 30 known substrates of PTK6, including signal transducers, transcription factors, and RNA-binding proteins. Many of these substrates are known drivers of other cancer types, such as colorectal cancer. Colon and rectal tumors also express higher levels of PTK6 than the normal intestine suggesting a potential role in tumorigenesis. However, the importance of PTK6 in colorectal cancer remains unclear. PTK6 inhibitors such as XMU-MP-2 and Tilfrinib have demonstrated potency and selectivity in breast cancer cells when used in combination with chemotherapy, indicating the potential for PTK6 targeted therapy in cancer. However, most of these inhibitors are yet to be tested in other cancer types. Here, we discuss the current understanding of the function of PTK6 in normal intestinal cells compared with colorectal cancer cells. We review existing PTK6 targeting therapeutics and explore the possibility of PTK6 inhibitory therapy for colorectal cancer.
PTK6是一种非受体酪氨酸激酶，可调节乳腺癌和前列腺癌的发病机制，被认为是乳腺癌预后的生物标志物。已知PTK6有30多种底物，包括信号转导子、转录因子和RNA结合蛋白。这些底物中的许多是其他癌症类型（如结直肠癌）的已知驱动因子。结肠和直肠肿瘤中PTK6的表达水平也高于正常肠道，提示其在肿瘤发生中可能发挥作用。然而，PTK6在结直肠癌中的重要性仍不清楚。PTK6抑制剂如XMU-MP-2和Tilfrinib与化疗联合使用时，已在乳腺癌细胞中显示出效力和选择性，表明PTK6靶向治疗癌症具有潜力。然而，这些抑制剂中的大多数尚未在其他癌症类型中进行测试。在此，我们讨论了与结直肠癌细胞相比，目前对PTK6在正常肠道细胞中功能的理解。我们回顾了现有的靶向PTK6的治疗方法，并探讨了PTK6抑制疗法用于结直肠癌的可能性。
